KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue (2016 - 2024)

Alnylam Pharmaceuticals' Non-Current Deffered Revenue history spans 16 years, with the latest figure at $1.0 million for Q3 2024.

  • For Q3 2024, Non-Current Deffered Revenue fell 99.48% year-over-year to $1.0 million; the TTM value through Sep 2024 reached $1.0 million, down 99.48%, while the annual FY2023 figure was $188.2 million, 2.9% down from the prior year.
  • Non-Current Deffered Revenue reached $1.0 million in Q3 2024 per ALNY's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $306.1 million in Q1 2020 to a low of $1.0 million in Q3 2024.
  • Average Non-Current Deffered Revenue over 5 years is $180.9 million, with a median of $191.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 63942.68% in 2020, then tumbled 99.48% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $225.1 million in 2020, then crashed by 32.31% to $152.4 million in 2021, then increased by 27.19% to $193.8 million in 2022, then dropped by 2.9% to $188.2 million in 2023, then crashed by 99.46% to $1.0 million in 2024.
  • Per Business Quant, the three most recent readings for ALNY's Non-Current Deffered Revenue are $1.0 million (Q3 2024), $2.4 million (Q2 2024), and $185.5 million (Q1 2024).